Agios leukemia drug shows promise in tiny, early study

[riky]

Agios leukemia drug shows promise in tiny, early study

An experimental drug being developed by Agios Pharmaceuticals Inc showed promising anti-cancer activity in a tiny Phase I study of patients with relapsed acute myeloid leukemia (AML), according to data presented on Sunday. Three of them achieved complete remission and two achieved complete remission with incomplete platelet recovery, meaning that the leukemia had exited their bone marrow but the blood platelet count had not yet returned to normal levels. "I'm very excited about what has happened with those patients so far who have responded," the study's lead investigator, Dr. Eytan Stein of Memorial Sloan Kettering Cancer Center in New York, said in a telephone interview. AML, the most common type of acute leukemia in adults, is a cancer of the blood and bone marrow that progresses quickly if left untreated.

Source: You are not allowed to view links. Register or Login